Patient-Reported Outcomes as Endpoints in Oncology Labeling Claims: An FDA/EMA Perspective
This blog post details the differences in approaches between FDA and EMA that are critical for sponsors to develop PRO strategies for drug labeling claims.
This blog post details the differences in approaches between FDA and EMA that are critical for sponsors to develop PRO strategies for drug labeling claims.